Incyte Corp (INCY)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$98.30

Buy

$99.61

arrow-up$3.23 (+3.39%)

Prices updated at 15 Dec 2025, 13:59 EST

Prices minimum 15 mins delay

Prices in USD

Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

NASDAQ

-0.59%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	3,696m	4,241m
	3,441m	3,929m
	650m	101m
	17.58	2.39
	598m	33m
	919m	408m
Sales, General and administrative	1,161m	1,222m
Interest expenses	3m	2m
Provision for income taxes	237m	284m
Operating expenses	2,791m	3,828m
Income before taxes	834m	317m
Net income available to common shareholders	598m	33m
	2.67	0.16
Net interest income	156m	126m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	2.65	0.15
Free cash flow per share	2.509	0.078
Book value/share	21.9872	16.3943
Debt equity ratio	0.005619	0.009729

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	4,645m	3,239m
Current liabilities	1,240m	1,642m
Total capital	5,190m	3,448m
Total debt	38m	44m
Total equity	5,190m	3,448m
Total non current liabilities	-	-
Loans	-	-
Total assets	6,782m	5,444m
Total liabilities	-	-
Cash and cash equivalents	3,213m	1,688m
Common stock	224m	193m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	2,953m	3,215m
Cash dividends paid	-	-
	449m	235m
Investments (gains) losses	-208m	158m
	3,215m	1,689m
Net income	-	-
	496m	335m
	-47m	-100m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.